Mixed Signals from FDA
Waiting to Exhale: COPD Push 'Daxas' Patience of Developers
By Randy Osborne
Monday, April 19, 2010
"The most bizarre we've ever seen." That's how Jefferies & Co. analyst Corey Davis described the FDA advisory panel meeting earlier this month on Daxas (roflumilast), the drug candidate for chronic obstructive pulmonary disease from Forest Laboratories Inc. and Nycomed GmbH.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.